135 related articles for article (PubMed ID: 7993989)
1. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
Degen PH; Flesch G; Cardot JM; Czendlik C; Dieterle W
Biopharm Drug Dispos; 1994 Aug; 15(6):519-26. PubMed ID: 7993989
[TBL] [Abstract][Full Text] [Related]
2. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
[TBL] [Abstract][Full Text] [Related]
3. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers.
Cardot JM; Lecaillon JB; Czendlik C; Godbillon J
Biopharm Drug Dispos; 1998 May; 19(4):259-62. PubMed ID: 9604126
[TBL] [Abstract][Full Text] [Related]
4. Influence of food on the disposition of the monoamine oxidase-A inhibitor brofaromine in healthy volunteers.
Degen PH; Cardot JM; Czendlik C; Dieterle W
Biopharm Drug Dispos; 1993 Apr; 14(3):209-15. PubMed ID: 8490109
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
[TBL] [Abstract][Full Text] [Related]
8. Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
Clemens PL; Cloyd JC; Kriel RL; Remmel RP
Clin Drug Investig; 2007; 27(4):243-50. PubMed ID: 17358096
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
[TBL] [Abstract][Full Text] [Related]
10. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine.
Keränen T; Sorri A; Moilanen E; Ylitalo P
Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of oxcarbazepine oral suspension vs. film-coated tablet in healthy Chinese male subjects.
Souppart C; Yin Q; Merz M; Hu P; Jiang J; Appel-Dingemanse S
Int J Clin Pharmacol Ther; 2008 Oct; 46(10):538-44. PubMed ID: 18826868
[TBL] [Abstract][Full Text] [Related]
12. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
[TBL] [Abstract][Full Text] [Related]
13. Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects.
Flesch G; Tudor D; Souppart C; D'Souza J; Hossain M
Int J Clin Pharmacol Ther; 2002 Nov; 40(11):524-32. PubMed ID: 12698990
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
15. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.
Rouan MC; Lecaillon JB; Godbillon J; Menard F; Darragon T; Meyer P; Kourilsky O; Hillion D; Aldigier JC; Jungers P
Eur J Clin Pharmacol; 1994; 47(2):161-7. PubMed ID: 7859804
[TBL] [Abstract][Full Text] [Related]
16. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
[TBL] [Abstract][Full Text] [Related]
20. Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers.
Antunes NJ; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Marques MP; Lanchote VL
J Pharm Biomed Anal; 2018 Feb; 149():442-447. PubMed ID: 29169112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
